Summit Therapeutics Inc(NASDAQ:SMMT) 
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product ca...
Website: http://www.summitplc.com
Founded: 2003
Full Time Employees: 70
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating expenses: | |||||||||||||||||||||||
research and development | 132,618,000 | 147,292,000 | 131,096,000 | 208,021,000 | 51,265,000 | 51,382,000 | 37,724,000 | 30,798,000 | 30,873,000 | 24,814,000 | 15,323,000 | 9,451,000 | 9,883,000 | 5,386,000 | 17,049,000 | 9,008,000 | 20,556,000 | 23,107,000 | 19,943,000 | 23,923,000 | 18,379,000 | 94,253,000 | -14,387,000 |
general and administrative | 62,594,000 | 77,633,000 | 103,115,000 | 360,416,000 | 15,586,000 | 14,437,000 | 20,390,000 | 13,971,000 | 11,729,000 | 11,575,000 | 5,434,000 | 6,316,000 | 6,940,000 | 7,578,000 | 5,573,000 | 6,933,000 | 6,659,000 | 7,780,000 | 5,662,000 | 5,984,000 | 4,185,000 | 32,662,000 | -7,460,000 |
total operating expenses | 195,212,000 | 224,925,000 | 234,211,000 | 568,437,000 | 66,851,000 | 65,819,000 | 58,114,000 | 59,776,000 | 42,602,000 | 36,389,000 | 20,757,000 | 15,767,000 | 537,738,000 | 21,432,000 | 22,622,000 | 15,941,000 | 27,215,000 | 30,887,000 | 25,605,000 | 29,907,000 | 22,564,000 | 128,633,000 | -22,706,000 |
other income | 5,788,000 | 5,753,000 | 2,418,000 | 2,729,000 | 3,938,000 | 13,097,000 | 2,124,000 | -768,000 | -1,230,250 | -776,000 | 1,077,000 | -5,222,000 | 761,000 | -1,052,000 | -113,000 | -686,000 | -565,000 | -13,000 | 416,000 | ||||
net income | -189,424,000 | -219,172,000 | -231,793,000 | -565,708,000 | -62,913,000 | -61,203,000 | -56,254,000 | -60,385,000 | -43,473,000 | -36,567,000 | -21,268,000 | -14,717,000 | -542,376,000 | -19,229,000 | -21,385,000 | -16,771,000 | -21,397,000 | -27,099,000 | -19,599,000 | -24,416,000 | -17,488,000 | -13,442,000 | -17,701,000 |
yoy | 201.09% | 258.11% | 312.05% | 836.84% | 44.72% | 67.37% | 164.50% | 310.31% | -91.98% | 90.17% | -0.55% | -12.25% | 2434.82% | -29.04% | 9.11% | -31.31% | 22.35% | 101.60% | 10.72% | ||||
qoq | -13.57% | -5.44% | -59.03% | 799.19% | 2.79% | 8.80% | -6.84% | 38.90% | 18.89% | 71.93% | 44.51% | -97.29% | 2720.61% | -10.08% | 27.51% | -21.62% | -21.04% | 38.27% | -19.73% | 39.62% | 30.10% | -24.06% | |
net income margin % | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | NaN% | -Infinity% | -Infinity% | -Infinity% | NaN% | NaN% | NaN% | -Infinity% | -9720.45% | -7136.60% | -8558.80% | -10796.41% | -1497.25% | -42835.09% | -9108.33% | -7265.95% | -9779.56% |
net income per share | |||||||||||||||||||||||
basic and diluted | -0.24 | -0.28 | -0.31 | -0.76 | -0.09 | -0.09 | -0.08 | -0.09 | -0.06 | -0.01 | -0.03 | -0.02 | -1.43 | 0.11 | -0.14 | -0.17 | -0.22 | -0.28 | -0.2 | ||||
weighted-average common shares outstanding: | |||||||||||||||||||||||
basic and diluted | 775,458,141 | 747,702,265 | 743,415,917 | 742,615,007 | 738,076,003 | 718,541,896 | 726,656,045 | 707,904,643 | 701,785,250 | 619,646,180 | 697,739,477 | 697,685,365 | 378,163,980 | 193,336,063 | 148,582,751 | 99,654,092 | 98,070,095 | 92,239,306 | 97,452,628 | 90,650,854 | 82,817,836 | ||
other comprehensive income: | |||||||||||||||||||||||
foreign currency translation adjustments | 84 | -36 | 43 | -189 | -145 | 235 | -155 | 92 | -12 | -152 | 108 | -76 | -51 | 1,324 | -49 | 789 | -1,760 | 1,245 | -863 | ||||
unrealized loss on short-term investments | -176 | ||||||||||||||||||||||
comprehensive loss | -189,516 | -219,003 | -231,750 | -565,897 | -63,191 | -61,180 | -56,063 | -60,335 | -43,474 | -36,692 | -21,154 | -15,758 | -541,878 | -17,905 | -21,434 | -15,982 | -23,157 | -25,854 | -20,462 | -23,876 | -16,813 | ||
acquired in-process research and development | |||||||||||||||||||||||
interest expense | |||||||||||||||||||||||
other comprehensive gain: | |||||||||||||||||||||||
reclassification of unrealized loss on short-term investments to other expense | |||||||||||||||||||||||
unrealized gain on short-term investments | 205 | ||||||||||||||||||||||
other comprehensive loss: | |||||||||||||||||||||||
unrealized gains on short-term investments | -133 | ||||||||||||||||||||||
revenue | 220,000 | 235,000 | 250,000 | 251,000 | 1,309,000 | 57,000 | 192,000 | 185,000 | 181,000 | ||||||||||||||
yoy | NaN% | NaN% | NaN% | NaN% | -83.19% | 312.28% | 30.21% | 35.68% | 623.20% | ||||||||||||||
qoq | NaN% | NaN% | -6.38% | -6.00% | -0.40% | -80.83% | 2196.49% | -70.31% | 3.78% | 2.21% | |||||||||||||
other operating income | 205,000 | -264,000 | 159,000 | 213,000 | 179,000 | 265,000 | -27,000 | 584,000 | 1,133,000 | 5,462,000 | 3,014,000 | 4,807,000 | 4,589,000 | 4,810,000 | 6,120,000 | 5,449,000 | 4,363,000 | 4,309,000 | |||||
operating income | -65,614,000 | -58,378,000 | -59,617,000 | -42,389,000 | -36,210,000 | -20,492,000 | -15,794,000 | -537,154,000 | -20,299,000 | -16,940,000 | -12,692,000 | -22,158,000 | -26,047,000 | -19,486,000 | -23,730,000 | -16,923,000 | -9,911,000 | -18,216,000 | |||||
yoy | 81.20% | 184.88% | 277.47% | -92.11% | 78.38% | 20.97% | 24.44% | 2324.20% | -22.07% | -13.07% | -46.51% | 30.93% | 162.81% | 6.97% | |||||||||
qoq | 12.40% | -2.08% | 40.64% | 17.06% | 76.70% | 29.75% | -97.06% | 2546.21% | 19.83% | 33.47% | -42.72% | -14.93% | 33.67% | -17.88% | 40.22% | 70.75% | -45.59% | ||||||
operating margin % | NaN% | NaN% | NaN% | NaN% | NaN% | -Infinity% | NaN% | -Infinity% | -Infinity% | -Infinity% | NaN% | NaN% | NaN% | -Infinity% | -7700.00% | -5400.85% | -8863.20% | -10377.29% | -1488.62% | -41631.58% | -8814.06% | -5357.30% | -10064.09% |
weighted-average shares used for eps calculation | |||||||||||||||||||||||
basic and diluted | 775,458,141 | 747,702,265 | 743,415,917 | 742,615,007 | 738,076,003 | 718,541,896 | 726,656,045 | 707,904,643 | 701,785,250 | 619,646,180 | 697,739,477 | 697,685,365 | 378,163,980 | 193,336,063 | 148,582,751 | 99,654,092 | 98,070,095 | 92,239,306 | 97,452,628 | 90,650,854 | 82,817,836 | ||
comprehensive loss: | |||||||||||||||||||||||
reclassification of cumulative currency translation gain to other expense | |||||||||||||||||||||||
net unrealized gains on short-term investments | 78 | 346 | |||||||||||||||||||||
acquired in process research and development | 15,007,000 | ||||||||||||||||||||||
reclassification of unrealized loss on investments to other expense | 3 | ||||||||||||||||||||||
net changes related to short-term investments | -45 | 11 | 2.25 | 6 | -965 | ||||||||||||||||||
in-process research and development | 520,915,000 | ||||||||||||||||||||||
other expense | -1,084,000 | 1,070,000 | -4,445,000 | -4,079,000 | |||||||||||||||||||
reclassification of cumulative currency translation gain to other income | -104.75 | -419 | |||||||||||||||||||||
unrealized gain on investments | 968 | ||||||||||||||||||||||
impairment of intangible assets | |||||||||||||||||||||||
loss before income tax | -27,099,000 | -19,599,000 | -24,416,000 | -9,837,000 | -17,800,000 | ||||||||||||||||||
income tax benefit | 23,250 | 99,000 | |||||||||||||||||||||
loss per share: | |||||||||||||||||||||||
basic and diluted | -0.27 | -0.21 | |||||||||||||||||||||
change in foreign currency translation adjustment | 540 | 675 | |||||||||||||||||||||
loss before income tax expense | -17,488,000 | ||||||||||||||||||||||
income tax expense | |||||||||||||||||||||||
operating expenses | |||||||||||||||||||||||
impairment | -214,750 | -859,000 | |||||||||||||||||||||
basic loss per share | -0.145 | -0.26 | |||||||||||||||||||||
diluted loss per share | -0.145 | -0.26 | |||||||||||||||||||||
other comprehensive income | |||||||||||||||||||||||
foreign currency translation adjustment | -578 | 2,255 | |||||||||||||||||||||
total comprehensive loss | -10,391.75 | -15,446 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-04-30 | 2020-03-31 | 2019-12-31 | 2019-10-31 | 2019-07-31 | 2019-04-30 | 2019-01-31 | 2018-10-31 | 2018-07-31 | 2018-04-30 | 2018-04-11 | 2018-01-31 | 2017-12-06 | 2017-08-31 | 2017-06-14 | 2017-03-29 | 2016-12-15 | 2016-09-08 | 2016-06-02 | 2016-05-10 | 2016-01-31 | 2015-12-17 | 2015-08-27 | 2015-06-11 | 2015-05-06 | 2015-01-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | |||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 106,515,000 | 225,266,000 | 238,554,000 | 297,872,000 | 211,526,000 | 104,862,000 | 93,775,000 | 28,434,000 | 61,294,000 | 71,425,000 | 23,792,000 | 42,116,000 | 70,969,000 | 348,607,000 | 121,971,000 | 103,386,000 | 102,194,000 | 66,417,000 | 21,270,000 | 64,245 | 55,296 | 48,417 | 17,600 | 25,498 | 36,894 | 26,858 | 16,669 | 22,482 | 38,070 | 28,525 | 20,102 | 42,250 | 37,333 | 25,050 | 35,316 | 42,293 | 9,283 | 14,650 | 23,125 | 16,304 | 34,272 | 41,328 | 45,086 | 16,927 | 11,265 | ||||
restricted cash | 316,000 | 316,000 | 321,000 | 319,000 | 318,000 | 325,000 | 323,000 | 320,000 | 317,000 | 300,000,000 | |||||||||||||||||||||||||||||||||||||||
short-term investments | 492,216,000 | 488,182,000 | 149,789,000 | 307,487,000 | 393,122,000 | 297,035,000 | 95,386,000 | 114,817,000 | 175,153,000 | 172,898,000 | 170,963,000 | ||||||||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | 17,551,000 | 6,537,000 | 7,591,000 | 11,049,000 | 9,118,000 | 10,519,000 | 2,410,000 | 2,052,000 | 5,323,000 | ||||||||||||||||||||||||||||||||||||||||
total current assets | 616,598,000 | 720,301,000 | 246,466,000 | 309,240,000 | 370,751,000 | 423,750,000 | 490,290,000 | 328,794,000 | 163,265,000 | 189,712,000 | 204,951,000 | 227,501,000 | 248,027,000 | 656,712,000 | 137,119,000 | 79,398,000 | 99,435,000 | 97,312,000 | 102,210,000 | 121,482,000 | 125,217,000 | 87,674,000 | 42,077,000 | ||||||||||||||||||||||||||
non-current assets: | |||||||||||||||||||||||||||||||||||||||||||||||||
property and equipment | 1,664,000 | 1,059,000 | 810,000 | 690,000 | 652,000 | 254,000 | 265,000 | 223,000 | 181,000 | 204,000 | 229,000 | 225,000 | 412,000 | 906,000 | 930,000 | 1,095,000 | 965,000 | 694,000 | 656,000 | 757,000 | 684,000 | 725,000 | |||||||||||||||||||||||||||
operating lease right-of-use assets | 19,398,000 | 20,616,000 | 5,420,000 | 5,552,000 | 6,351,000 | 7,144,000 | |||||||||||||||||||||||||||||||||||||||||||
goodwill | 1,965,000 | 2,001,000 | 1,999,000 | 2,039,000 | 1,923,000 | 1,864,000 | 1,991,000 | 1,880,000 | 1,875,000 | 1,893,000 | 1,814,000 | 1,883,000 | 1,839,000 | 1,798,000 | 1,655,000 | 1,806,000 | 1,953,000 | 2,009,000 | 2,001,000 | 2,057,000 | 2,047,000 | 2,030,000 | 2,335,000 | 2,407 | 2,259 | 1,814 | 2,347 | 2,217 | 2,364 | 1,814 | 2,318 | 2,381 | 3,407 | 3,516 | 2,478 | 882 | 876 | 859 | 836 | 811 | 881 | 974 | 941 | 664 | 1,026 | 1,038 | 1,018 | 998 | 664 |
other assets | 8,231,000 | 7,205,000 | 7,034,000 | 6,516,000 | 4,145,000 | 1,850,000 | 1,863,000 | 1,879,000 | 1,875,000 | 4,322,000 | 4,332,000 | 254,000 | 156,000 | 577,000 | 140,000 | 179,000 | 166,000 | 170,000 | |||||||||||||||||||||||||||||||
total assets | 647,856,000 | 751,182,000 | 261,729,000 | 324,037,000 | 383,822,000 | 435,560,000 | 502,852,000 | 341,856,000 | 176,781,000 | 202,949,000 | 218,476,000 | 237,372,000 | 254,897,000 | 664,168,000 | 155,327,000 | 95,718,000 | 116,472,000 | 113,374,000 | 128,673,000 | 145,517,000 | 140,794,000 | 102,498,000 | 56,865,000 | 97,027 | 89,411 | 73,123 | 50,913 | 59,172 | 69,908 | 59,767 | 57,286 | 61,394 | 87,650 | 76,573 | 53,962 | 64,643 | 54,311 | 39,983 | 47,304 | 52,456 | 19,413 | 29,628 | 35,565 | 25,076 | 45,472 | 52,534 | 57,167 | 29,146 | 19,396 |
liabilities and stockholders' equity | |||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 27,549,000 | 20,292,000 | 22,245,000 | 22,982,000 | 4,994,000 | 4,636,000 | 3,252,000 | 3,340,000 | 6,371,000 | 2,667,000 | 3,314,000 | 987,000 | 710,000 | 355,000 | 1,431,000 | 3,574,000 | 6,959,000 | 4,374,000 | 5,875,000 | 6,949,000 | 4,114,000 | 6,140,000 | 2,493,000 | ||||||||||||||||||||||||||
accrued liabilities | 44,317,000 | 32,100,000 | 27,042,000 | 26,148,000 | 21,185,000 | 19,554,000 | 18,477,000 | 12,457,000 | 6,547,000 | 8,783,000 | 10,664,000 | 7,197,000 | 4,261,000 | ||||||||||||||||||||||||||||||||||||
accrued compensation | 7,073,000 | 14,925,000 | 10,965,000 | 6,592,000 | 4,396,000 | 11,977,000 | 7,961,000 | 4,877,000 | 6,033,000 | 5,429,000 | 3,510,000 | 3,529,000 | 2,416,000 | 5,641,000 | 2,509,000 | 1,906,000 | 1,514,000 | 4,125,000 | |||||||||||||||||||||||||||||||
operating lease liabilities, current portion | 3,179,000 | 3,388,000 | 2,720,000 | 3,118,000 | 3,543,000 | 3,765,000 | |||||||||||||||||||||||||||||||||||||||||||
other current liabilities | 1,148,000 | 2,283,000 | 1,956,000 | 1,485,000 | 759,000 | 1,797,000 | 1,027,000 | 806,000 | 788,000 | 717,000 | 484,000 | 619,000 | 320,000 | 662,000 | 209,000 | 265,000 | 678,000 | 897,000 | 1,030,000 | 661,000 | 581,000 | 729,000 | 354,000 | ||||||||||||||||||||||||||
total current liabilities | 83,266,000 | 72,988,000 | 64,928,000 | 60,325,000 | 34,877,000 | 41,729,000 | 59,009,000 | 140,168,000 | 23,438,000 | 20,405,000 | 113,742,000 | 11,931,000 | 17,443,000 | 38,782,000 | 16,682,000 | 15,173,000 | 22,724,000 | 25,623,000 | 22,789,000 | 21,888,000 | 73,052,000 | 19,890,000 | 14,742,000 | ||||||||||||||||||||||||||
non-current liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||
operating lease liabilities, net of current portion | 16,859,000 | 17,502,000 | 2,708,000 | 2,435,000 | 2,907,000 | 3,453,000 | |||||||||||||||||||||||||||||||||||||||||||
other non-current liabilities | 1,799,000 | 1,832,000 | 1,830,000 | 1,838,000 | 1,708,000 | 1,630,000 | 1,716,000 | 1,596,000 | 3,310,000 | 1,562,000 | 1,476,000 | 1,511,000 | 1,481,000 | 1,429,000 | 2,424,000 | 2,594,000 | 2,751,000 | 2,776,000 | 2,690,000 | 2,689,000 | 2,603,000 | 2,511,000 | 2,277,000 | ||||||||||||||||||||||||||
total liabilities | 101,924,000 | 92,322,000 | 69,466,000 | 64,598,000 | 39,492,000 | 46,812,000 | 64,932,000 | 146,781,000 | 132,571,000 | 125,257,000 | 119,097,000 | 117,773,000 | 121,415,000 | 537,514,000 | 22,079,000 | 44,401,000 | 52,065,000 | 30,090,000 | 26,375,000 | 26,090,000 | 76,389,000 | 23,045,000 | 20,004,000 | -18,441 | -13,898 | -17,225 | -79,710 | -62,561 | -44,087 | -43,253 | -49,693 | -50,307 | -51,700 | -51,126 | -5,389 | -5,678 | -5,591 | -3,943 | -5,449 | -5,295 | -5,247 | -6,658 | -4,430 | ||||||
commitments and contingencies | |||||||||||||||||||||||||||||||||||||||||||||||||
stockholders' equity: | |||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 0.01 par value... | |||||||||||||||||||||||||||||||||||||||||||||||||
common stock | 7,760,000 | 7,754,000 | 7,444,000 | 7,428,000 | 7,416,000 | 7,376,000 | 7,371,000 | 7,243,000 | 7,020,000 | 7,017,000 | 6,978,000 | 6,976,000 | 6,976,000 | 2,110,000 | 2,013,000 | 981,000 | 981,000 | 980,000 | 976,000 | 974,000 | 829,000 | 826,000 | 672,000 | ||||||||||||||||||||||||||
additional paid-in capital | 3,024,387,000 | 2,947,805,000 | 2,262,515,000 | 2,097,957,000 | 1,616,963,000 | 1,598,230,000 | 1,586,227,000 | 1,287,447,000 | 1,076,370,000 | 1,066,381,000 | 1,051,415,000 | 1,050,483,000 | 1,048,608,000 | 504,767,000 | 493,553,000 | 391,220,000 | 388,328,000 | 384,049,000 | 377,213,000 | 373,882,000 | 295,129,000 | 293,367,000 | 242,395,000 | ||||||||||||||||||||||||||
accumulated other comprehensive loss | -2,632,000 | -2,540,000 | -2,709,000 | -2,752,000 | -2,563,000 | -2,285,000 | -2,308,000 | -2,499,000 | -2,449,000 | -2,448,000 | -2,323,000 | -2,437,000 | -1,396,000 | -1,893,000 | -3,217,000 | -3,168,000 | -3,957,000 | -2,197,000 | -3,442,000 | -2,579,000 | -3,119,000 | -3,794,000 | -7,032,000 | ||||||||||||||||||||||||||
accumulated deficit | -2,483,583,000 | -2,294,159,000 | -2,074,987,000 | -1,843,194,000 | -1,277,486,000 | -1,214,573,000 | -1,153,370,000 | -1,097,116,000 | -1,036,731,000 | -993,258,000 | -956,691,000 | -935,423,000 | -920,706,000 | -378,330,000 | -359,101,000 | -337,716,000 | -320,945,000 | -299,548,000 | -272,449,000 | -252,850,000 | -228,434,000 | -210,946,000 | -199,174,000 | ||||||||||||||||||||||||||
total stockholders' equity | 545,932,000 | 658,860,000 | 192,263,000 | 259,439,000 | 344,330,000 | 388,748,000 | 437,920,000 | 195,075,000 | 44,210,000 | 99,379,000 | 119,599,000 | 133,482,000 | 126,654,000 | 133,248,000 | 51,317,000 | 64,407,000 | 83,284,000 | 102,298,000 | 119,427,000 | 64,405,000 | 79,453,000 | 36,861,000 | |||||||||||||||||||||||||||
total liabilities and stockholders' equity | 647,856,000 | 751,182,000 | 261,729,000 | 324,037,000 | 383,822,000 | 435,560,000 | 502,852,000 | 341,856,000 | 176,781,000 | 218,476,000 | 237,372,000 | 254,897,000 | 664,168,000 | 155,327,000 | 95,718,000 | 116,472,000 | 113,374,000 | 128,673,000 | 145,517,000 | 140,794,000 | 102,498,000 | 56,865,000 | |||||||||||||||||||||||||||
liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity: | |||||||||||||||||||||||||||||||||||||||||||||||||
research and development tax credit receivable | 557,000 | 660,000 | 953,000 | 945,000 | 848,000 | 812,000 | 4,607,000 | 4,500,000 | 5,766,000 | 12,958,000 | 14,132,000 | 15,290,000 | 15,695,000 | 10,072,000 | 9,856,000 | ||||||||||||||||||||||||||||||||||
promissory note payable to a related party | 24,500,000 | 100,000,000 | 100,000,000 | 100,000,000 | 25,312,000 | 25,055,000 | 54,963,000 | ||||||||||||||||||||||||||||||||||||||||||
right-of-use assets | 7,976,000 | 8,716,000 | 9,373,000 | 5,859,000 | 6,403,000 | 6,996,000 | 3,928,000 | 4,175,000 | 4,230,000 | 2,017,000 | 2,432,000 | 2,790,000 | 1,884,000 | 2,212,000 | 1,487,000 | 554,000 | 628,000 | ||||||||||||||||||||||||||||||||
lease liabilities | 3,792,000 | 3,688,000 | 3,699,000 | 2,809,000 | 2,780,000 | 2,928,000 | 1,693,000 | 1,690,000 | 1,392,000 | 684,000 | 907,000 | 1,091,000 | 941,000 | 1,006,000 | 1,056,000 | 390,000 | 386,000 | -424 | -320 | ||||||||||||||||||||||||||||||
lease liabilities, net of current portion | 4,207,000 | 5,017,000 | 5,823,000 | 3,290,000 | 3,879,000 | 4,331,000 | 2,491,000 | 2,763,000 | 2,973,000 | 1,322,000 | 1,535,000 | 1,691,000 | |||||||||||||||||||||||||||||||||||||
accrued acquired in-process research and development | 15,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | 349,000 | 140,000 | 238,000 | 870,000 | 1,464,000 | 2,290,000 | 1,053,000 | 447,000 | 4,080,000 | ||||||||||||||||||||||||||||||||||||||||
prepaid expenses | 2,441,000 | 5,074,000 | 6,093,000 | 1,186,000 | 1,504,000 | 1,622,000 | 5,393,000 | 4,350,000 | 7,161,000 | 8,409,000 | 5,727,000 | 7,995,000 | 9,547,000 | 7,141,000 | |||||||||||||||||||||||||||||||||||
other current assets | 181,000 | 120,000 | 1,787,000 | 409,000 | 486,000 | 428,000 | 2,300,000 | 1,475,000 | 1,201,000 | 1,191,000 | 963,000 | 985,000 | 1,523,000 | 1,667,000 | |||||||||||||||||||||||||||||||||||
promissory note payable to related parties | 19,770,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
non-current liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||
promissory notes payable to related parties | 100,000,000 | 494,540,000 | |||||||||||||||||||||||||||||||||||||||||||||||
total stockholders’ equity | 77,692,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and stockholders’ equity | 202,949,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses | 3,654,000 | 3,868,000 | 12,304,000 | 11,141,000 | 5,513,000 | 7,569,000 | 7,432,000 | 6,132,000 | 4,915,000 | 4,398,000 | |||||||||||||||||||||||||||||||||||||||
intangible assets | 7,952,000 | 8,900,000 | 9,866,000 | 10,399,000 | 10,608,000 | 11,161,000 | 11,359,000 | 11,515,000 | 11,101,000 | 13,203 | 12,292 | 9,950 | 13,049 | 12,574 | 13,547 | 10,604 | 13,835 | 14,481 | 20,053 | 20,980 | 14,785 | 4,551 | 4,526 | 4,440 | 4,368 | 4,241 | 4,612 | 5,096 | 4,926 | 3,473 | 5,369 | 5,438 | 5,334 | 5,234 | 3,483 | ||||||||||||||
deferred revenue and other income | 3,231,000 | 5,097,000 | 7,939,000 | ||||||||||||||||||||||||||||||||||||||||||||||
cash | 57,335,000 | 77,450,000 | 71,791,000 | 80,248,000 | |||||||||||||||||||||||||||||||||||||||||||||
deferred revenue and other income, net of current portion | |||||||||||||||||||||||||||||||||||||||||||||||||
deferred revenue | 7,511,000 | -496 | -374 | -831 | -35,181 | -25,589 | -18,033 | -24,478 | -26,602 | -28,317 | |||||||||||||||||||||||||||||||||||||||
research and development tax credit receivables | 10,353,000 | 13,596,000 | 7,919,000 | ||||||||||||||||||||||||||||||||||||||||||||||
deferred revenue and income | 7,140,000 | 7,423,000 | 8,370,000 | -1,507 | -1,136 | -3,374 | |||||||||||||||||||||||||||||||||||||||||||
accounts and other receivable | 331,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
contingent consideration | -106 | -80 | -629 | ||||||||||||||||||||||||||||||||||||||||||||||
current assets | |||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment | 724,000 | 1,548 | 1,305 | 1,167 | 1,594 | 1,668 | 1,812 | 616 | 805 | 921 | 1,041 | 1,148 | 809 | 753 | 739 | 611 | 146 | 139 | 117 | 114 | 117 | 83 | 128 | 94 | 97 | 83 | 55 | ||||||||||||||||||||||
current liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||
deferred income | 7,111,000 | -29,719 | -30,948 | ||||||||||||||||||||||||||||||||||||||||||||||
deferred tax liability | 2,108,000 | -2,070 | -1,560 | -1,675 | -3,271 | -3,376 | -2,379 | -750 | -745 | -731 | -711 | -811 | -881 | -973 | -941 | -664 | -664 | ||||||||||||||||||||||||||||||||
stockholders'equity | |||||||||||||||||||||||||||||||||||||||||||||||||
non-current assets | |||||||||||||||||||||||||||||||||||||||||||||||||
non-current assets - sum | 17,158 | 15,856 | 12,931 | 16,990 | 16,459 | 17,723 | 13,034 | 16,958 | 17,783 | 24,501 | 25,644 | 18,072 | 6,186 | 6,141 | 5,191 | 5,610 | 6,184 | 5,984 | 4,220 | 6,523 | 6,570 | 6,449 | 6,315 | 4,202 | |||||||||||||||||||||||||
trade and other receivables | 10,769 | 12,179 | 8,116 | 11,583 | 13,049 | 12,324 | 13,547 | 2,940 | 3,952 | 2,630 | |||||||||||||||||||||||||||||||||||||||
current tax receivable | 4,855 | 6,080 | 3,659 | 4,740 | 4,166 | 2,967 | 6,328 | 7,281 | 6,038 | 7,791 | 6,605 | 4,654 | 11,136 | 9,019 | 7,071 | 5,346 | 3,624 | 2,683 | 3,014 | 1,299 | |||||||||||||||||||||||||||||
current assets - sum | 79,869 | 73,555 | 60,192 | 33,923 | 42,713 | 52,185 | 46,733 | 40,328 | 43,611 | 63,149 | 50,929 | 35,890 | 58,457 | 48,170 | 47,265 | 13,803 | 23,444 | 29,581 | 20,856 | 38,949 | 45,964 | 50,718 | 22,831 | 15,194 | |||||||||||||||||||||||||
liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||
provisions for other liabilities and charges | -2,720 | -2,050 | -1,851 | -2,320 | -2,329 | -1,641 | -199 | -198 | -129 | -107 | -104 | -113 | -117 | -103 | -102 | -92 | -78 | -68 | -45 | ||||||||||||||||||||||||||||||
non-current liabilities - sum | -5,710 | -4,304 | -4,357 | -45,215 | -35,679 | -25,143 | -28,873 | -35,940 | -38,828 | -994 | -1,090 | -1,044 | -737 | -1,026 | -1,038 | -1,018 | -998 | -664 | |||||||||||||||||||||||||||||||
trade and other payables | -10,643 | -8,020 | -8,865 | -16,371 | -12,675 | -8,932 | -5,200 | -4,632 | -4,130 | -5,016 | -3,858 | -4,395 | -4,588 | -4,547 | -3,206 | -4,321 | -4,165 | -4,151 | -5,592 | -3,721 | |||||||||||||||||||||||||||||
current liabilities - sum | -12,731 | -9,594 | -12,868 | -34,495 | -26,882 | -18,944 | -14,380 | -13,753 | -12,298 | -4,588 | -4,547 | -4,423 | -4,257 | -4,229 | -5,660 | -3,766 | |||||||||||||||||||||||||||||||||
net assets / | 78,586 | 42,542 | 35,825 | 43,385 | 7,940 | 14,012 | 9,875 | 21,390 | |||||||||||||||||||||||||||||||||||||||||
equity | |||||||||||||||||||||||||||||||||||||||||||||||||
share capital | 4,457 | 4,187 | 3,359 | 2,077 | 1,961 | 2,091 | 1,604 | 1,052 | 1,078 | 1,128 | 1,044 | 736 | 938 | 817 | 801 | 778 | 755 | 816 | 901 | 869 | 613 | 947 | 958 | 933 | 618 | 411 | |||||||||||||||||||||||
share premium account | 171,316 | 160,794 | 129,110 | 120,082 | 113,409 | 120,926 | 92,806 | 95,068 | 97,642 | 102,299 | 85,476 | 60,237 | 80,001 | 61,299 | 60,073 | 58,420 | 56,669 | 61,231 | 67,668 | 65,296 | 46,035 | 71,101 | 71,971 | 70,394 | 36,214 | 24,101 | |||||||||||||||||||||||
share-based payment reserve | 1,724 | 1,825 | 1,299 | 1,560 | 1,333 | 1,316 | 1,148 | 14,065 | 10,377 | 10,022 | 9,568 | 6,743 | 8,560 | 7,842 | 7,003 | 6,463 | 5,854 | 5,999 | 6,002 | 5,328 | 3,757 | 5,356 | 4,857 | 4,342 | 3,902 | 2,597 | |||||||||||||||||||||||
merger reserve | 4,017 | 3,770 | 3,027 | 3,917 | 3,699 | 3,944 | 3,027 | 3,868 | 3,973 | 4,162 | 4,295 | 3,027 | -2,580 | -2,564 | -2,513 | -2,445 | -2,372 | -2,578 | -2,849 | -2,755 | -1,943 | -3,001 | -3,038 | -2,978 | -2,920 | -1,943 | |||||||||||||||||||||||
special reserve | 26,529 | 24,899 | 19,993 | 25,869 | 24,431 | 26,051 | 19,993 | 25,549 | 26,241 | 27,492 | 28,370 | 19,993 | 26,553 | 26,383 | 25,867 | 25,161 | 24,415 | 26,531 | 29,322 | 28,358 | 19,993 | 30,879 | 31,257 | 30,645 | 30,041 | 19,993 | |||||||||||||||||||||||
currency translation reserve | 74 | 85 | 56 | 79 | 94 | 77 | 56 | 79 | 74 | 61 | 53 | 37 | 60 | 55 | 45 | 63 | 79 | 49 | 24 | 29 | 21 | 93 | 102 | 118 | 93 | 62 | |||||||||||||||||||||||
accumulated losses reserve | -129,531 | -97,619 | -76,092 | -137,224 | -114,794 | -80,898 | -92,142 | -89,214 | -101,600 | -92,836 | -84,070 | -78,024 | -77,118 | -67,151 | -47,343 | -65,352 | -58,868 | -51,534 | -45,460 | -30,255 | |||||||||||||||||||||||||||||
total equity / | 78,586 | 42,542 | 35,825 | 43,385 | 7,940 | 14,012 | 9,875 | 21,390 | |||||||||||||||||||||||||||||||||||||||||
net assets | 67,919 | 59,225 | 34,757 | 41,187 | 50,353 | 1,330 | 14,024 | 23,950 | 29,974 | 21,133 | 40,023 | 47,239 | 51,920 | 22,488 | 14,966 | ||||||||||||||||||||||||||||||||||
total equity | 67,919 | 59,225 | 34,757 | 41,187 | 50,353 | 1,330 | 14,024 | 23,950 | 29,974 | 21,133 | 14,966 | ||||||||||||||||||||||||||||||||||||||
financial liabilities on funding arrangements | -4,443 | -4,385 | -3,090 | -3,446 | -8,395 | -7,948 | -6,965 | ||||||||||||||||||||||||||||||||||||||||||
note | |||||||||||||||||||||||||||||||||||||||||||||||||
prepayments and other receivables | 16,378 | 15,091 | 17,288 | 15,799 | 11,134 | 5,071 | 1,818 | 1,952 | 1,292 | 1,348 | 1,837 | 2,998 | 2,181 | 1,538 | 1,767 | 2,891 | |||||||||||||||||||||||||||||||||
net assets/ | 4,618 | ||||||||||||||||||||||||||||||||||||||||||||||||
total equity/ | 4,618 | ||||||||||||||||||||||||||||||||||||||||||||||||
net liabilities | -10,324 | ||||||||||||||||||||||||||||||||||||||||||||||||
total deficit | -10,324 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||
income before income tax | -5,964 | -25,707 | |||||||||||||||||||||||||||||||||||||||||||||||
adjusted for: | |||||||||||||||||||||||||||||||||||||||||||||||||
finance income | -1 | -8 | |||||||||||||||||||||||||||||||||||||||||||||||
finance cost | 224 | 862 | |||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange loss | 473 | ||||||||||||||||||||||||||||||||||||||||||||||||
depreciation | 23 | 48 | |||||||||||||||||||||||||||||||||||||||||||||||
amortisation of intangible fixed assets | 2 | 10 | |||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of assets | 37 | ||||||||||||||||||||||||||||||||||||||||||||||||
movement in provisions | 12 | ||||||||||||||||||||||||||||||||||||||||||||||||
research and development expenditure credit | -3 | ||||||||||||||||||||||||||||||||||||||||||||||||
share-based payment | 277 | 1,379 | |||||||||||||||||||||||||||||||||||||||||||||||
adjusted income from operations before changes in working capital | -4,929 | -22,696 | |||||||||||||||||||||||||||||||||||||||||||||||
increase in prepayments and other receivables | -482 | ||||||||||||||||||||||||||||||||||||||||||||||||
decrease in deferred revenue | -1,728 | ||||||||||||||||||||||||||||||||||||||||||||||||
decrease in trade and other payables | -798 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash used by operations | -7,937 | ||||||||||||||||||||||||||||||||||||||||||||||||
taxation paid | -15 | ||||||||||||||||||||||||||||||||||||||||||||||||
net cash used by operating activities | -7,952 | ||||||||||||||||||||||||||||||||||||||||||||||||
investing activities | |||||||||||||||||||||||||||||||||||||||||||||||||
purchase of property, plant and equipment | -280 | -81 | |||||||||||||||||||||||||||||||||||||||||||||||
interest received | 1 | 8 | |||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities | -279 | -80 | |||||||||||||||||||||||||||||||||||||||||||||||
financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants | 10 | 107 | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of share options | 3 | 283 | |||||||||||||||||||||||||||||||||||||||||||||||
net cash generated from financing activities | 13 | 413 | |||||||||||||||||||||||||||||||||||||||||||||||
decrease in cash and cash equivalents | -8,218 | ||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rates in cash and cash equivalents | -482 | -716 | |||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of the period | 28,062 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of the period | 19,362 | ||||||||||||||||||||||||||||||||||||||||||||||||
financial liabilities on income arrangements | -7,449 | ||||||||||||||||||||||||||||||||||||||||||||||||
net (liabilities) / assets | -4,396 | ||||||||||||||||||||||||||||||||||||||||||||||||
total (deficit) / equity | -4,396 | ||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange loss / | 711 | ||||||||||||||||||||||||||||||||||||||||||||||||
decrease in prepayments and other receivables | 492 | ||||||||||||||||||||||||||||||||||||||||||||||||
increase in deferred income | 30,527 | ||||||||||||||||||||||||||||||||||||||||||||||||
increase / (decrease) in trade and other payables | 813 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash generated from / (used by) operations | 9,136 | ||||||||||||||||||||||||||||||||||||||||||||||||
taxation received | 3,005 | ||||||||||||||||||||||||||||||||||||||||||||||||
net cash generated from / (used by) operating activities | 12,141 | ||||||||||||||||||||||||||||||||||||||||||||||||
purchase of intangible assets | -7 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issue of share capital | |||||||||||||||||||||||||||||||||||||||||||||||||
transaction costs on share capital issued | |||||||||||||||||||||||||||||||||||||||||||||||||
cash received from funding arrangements accounted for as financial liabilities | 23 | ||||||||||||||||||||||||||||||||||||||||||||||||
increase in cash and cash equivalents | 12,474 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of the year | 16,304 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of the year | 28,062 | ||||||||||||||||||||||||||||||||||||||||||||||||
current tax | 5,796 | 4,275 | 2,910 | 1,745 | 2,692 | 1,952 | |||||||||||||||||||||||||||||||||||||||||||
provision for other liabilities and charges | -73 | ||||||||||||||||||||||||||||||||||||||||||||||||
deferred tax | -1,026 | -1,038 | -1,018 | -998 | |||||||||||||||||||||||||||||||||||||||||||||
total equity attributable to the equity shareholders of the parent | 40,023 | 47,239 | 51,920 | 22,488 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-03-31 | 2019-12-31 | 2019-10-31 | 2019-07-31 | 2019-04-30 | 2019-01-31 | 2018-10-31 | 2018-07-31 | 2018-05-15 | 2018-04-30 | 2018-01-31 | 2017-12-06 | 2017-08-31 | 2017-06-14 | 2017-01-31 | 2016-12-15 | 2016-09-08 | 2016-06-02 | 2016-01-31 | 2015-12-17 | 2015-08-27 | 2015-06-11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||
net loss | -189,424,000 | -219,172,000 | -62,913,000 | -61,203,000 | -56,254,000 | -36,567,000 | -21,268,000 | -14,717,000 | -542,376,000 | -19,229,000 | -21,385,000 | -16,771,000 | -21,397,000 | -27,099,000 | -19,599,000 | -24,416,000 | -17,488,000 | |||||||||||||||||||||||||||
adjustments to reconcile net loss to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||
amortization of discount on short-term investments | -4,217,000 | -3,017,000 | 0 | -1,023,000 | -2,966,000 | 2,350,000 | -2,919,000 | -1,605,000 | -402,000 | -208,000 | 1,185,000 | |||||||||||||||||||||||||||||||||
unrealized foreign exchange loss | 190,000 | 94,000 | -224,000 | 494,000 | -394,000 | -470,000 | -1,657,000 | 1,905,000 | 1,329,000 | 1,037,000 | ||||||||||||||||||||||||||||||||||
depreciation | 44,000 | 42,000 | 42,000 | 37,000 | 25,000 | 22,000 | 20,000 | 20,000 | 27,000 | 30,000 | 32,000 | 46,000 | 90,000 | 88,000 | 93,000 | 99,000 | 69,000 | 79,000 | 81,000 | 90,000 | 80,000 | 35,000 | 178 | 96 | 81 | 161 | 186 | 11 | 92 | -16 | 222 | 106 | 16 | 47 | 47 | 30 | 3 | 14 | 15 | 16 | -4 | 15 | ||
stock-based compensation | 72,791,000 | 111,779,000 | 130,761,000 | 478,784,000 | 11,096,000 | 11,015,000 | 19,371,000 | 11,088,000 | 9,507,000 | 8,753,000 | 705,000 | 1,875,000 | 2,775,000 | 2,658,000 | 2,798,000 | 2,496,000 | 3,996,000 | 5,620,000 | 2,644,000 | 3,672,000 | 868,000 | 578,000 | ||||||||||||||||||||||
change in operating assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | -11,014,000 | 1,208,000 | 3,739,000 | -1,931,000 | 1,850,000 | |||||||||||||||||||||||||||||||||||||||
other assets | -1,026,000 | -2,253,000 | -1,419,000 | |||||||||||||||||||||||||||||||||||||||||
accounts payable | 6,802,000 | -2,145,000 | -839,000 | 17,931,000 | 356,000 | 1,529,000 | -188,000 | -3,030,000 | 3,704,000 | -672,000 | 2,330,000 | 297,000 | 308,000 | -2,369,000 | -1,042,000 | -3,480,000 | 2,759,000 | -1,364,000 | -1,019,000 | 2,754,000 | -2,082,000 | 3,491,000 | ||||||||||||||||||||||
accrued liabilities | 12,218,000 | 945,000 | 4,841,000 | 1,611,000 | 6,096,000 | 5,952,000 | -2,154,000 | 5,351,000 | -200,000 | -8,258,000 | 730,000 | -35,000 | 5,895,000 | -246,000 | -832,000 | 1,134,000 | 1,175,000 | 2,102,000 | -100,000 | |||||||||||||||||||||||||
accrued compensation | -7,852,000 | 3,956,000 | 4,360,000 | 2,181,000 | -7,588,000 | 4,042,000 | 3,066,000 | -1,157,000 | 606,000 | 1,910,000 | -10,000 | 1,103,000 | -3,238,000 | 4,046,000 | 648,000 | 438,000 | -3,523,000 | |||||||||||||||||||||||||||
other current liabilities | -1,135,000 | 476,000 | 704,000 | -1,046,000 | ||||||||||||||||||||||||||||||||||||||||
other non-current liabilities | -33,000 | 30,000 | ||||||||||||||||||||||||||||||||||||||||||
operating lease right-of-use assets and lease liabilities | 365,000 | 267,000 | 6,000 | -95,000 | 25,000 | 48,000 | 37,000 | -160,000 | -92,000 | |||||||||||||||||||||||||||||||||||
net cash from operating activities | -122,291,000 | -101,938,000 | -93,080,000 | -66,744,000 | -61,168,000 | -48,673,000 | -30,297,000 | -33,002,000 | -30,134,000 | -19,459,000 | -14,897,000 | -29,273,000 | -13,131,000 | 5,191,000 | -8,555,000 | -19,217,000 | -19,001,000 | -9,179,000 | -23,565,000 | -19,174,000 | -20,669,000 | -7,971,000 | -3,199 | -9,338 | 80 | -6,383 | ||||||||||||||||||
capital expenditures | -245,000 | 127,000 | 21,000 | 0 | -422,000 | 0 | -58,000 | -63,000 | -4,000 | 0 | -53,000 | -20,000 | -53,000 | 0 | 20,000 | -293,000 | -361,000 | 0 | 0 | -151,000 | -39,000 | 0 | -27 | -10 | 25 | -53 | ||||||||||||||||||
free cash flows | -122,536,000 | -101,811,000 | -93,059,000 | -66,744,000 | -61,590,000 | -48,673,000 | -30,355,000 | -33,065,000 | -30,138,000 | -19,459,000 | -14,950,000 | -29,293,000 | -13,184,000 | 5,191,000 | -8,535,000 | -19,510,000 | -19,362,000 | -9,179,000 | -23,565,000 | -19,325,000 | -20,708,000 | -7,971,000 | -3,226 | -9,348 | 105 | -6,436 | ||||||||||||||||||
cash flows from investing activities: | ||||||||||||||||||||||||||||||||||||||||||||
maturities and sales of short-term investments | 177,293,000 | 0 | 0 | 150,808,000 | 160,532,000 | 232,984,000 | 73,999,000 | 69,997,000 | 112,857,000 | 60,569,000 | 109,425,000 | |||||||||||||||||||||||||||||||||
purchase of short-term investments | -177,286,000 | -149,488,000 | -167,549,000 | -270,013,000 | -92,982,000 | 1,000 | -112,858,000 | -38,170,000 | -169,995,000 | |||||||||||||||||||||||||||||||||||
purchases of property and equipment | -245,000 | -71,000 | 0 | -422,000 | -58,000 | -63,000 | -4,000 | -53,000 | -20,000 | -53,000 | 20,000 | -293,000 | -361,000 | |||||||||||||||||||||||||||||||
net cash from investing activities | -238,000 | -485,157,000 | -71,000 | 150,808,000 | 160,110,000 | 83,482,000 | -108,615,000 | -200,079,000 | 19,871,000 | 60,568,000 | -3,486,000 | 207,000 | -645,063,000 | 10,000 | 20,000 | -293,000 | -361,000 | -120,000 | 4,000 | -151,000 | -39,000 | -50,000 | -669 | -40 | -4,716 | -58 | -107 | -361 | -35 | -15 | -24 | -6 | ||||||||||||
cash flows from financing activities: | ||||||||||||||||||||||||||||||||||||||||||||
proceeds received related to employee stock purchase plan and exercise of stock options | 3,797,000 | |||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants | -3 | 0 | 0 | 13 | -24 | -11 | ||||||||||||||||||||||||||||||||||||||
net cash from financing activities | 3,797,000 | 573,821,000 | 33,813,000 | 2,222,000 | 7,677,000 | -23,612,000 | 204,142,000 | 200,212,000 | 485,000 | 6,252,000 | 229,000 | -80,000 | 80,112,000 | 520,060,000 | 74,997,000 | 0 | 25,187,000 | 1,261,000 | 676,000 | 20,082,000 | 55,897,000 | 50,548,000 | ||||||||||||||||||||||
effect of exchange rate changes on cash | -19,000 | 22,000 | 61,000 | 38,000 | 114,000 | 12,000 | -36,000 | -170,000 | 293,000 | 444,000 | -1,826,000 | -605,000 | -166,000 | |||||||||||||||||||||||||||||||
increase in cash, cash equivalents and restricted cash | -118,751,000 | -13,293,000 | -59,316,000 | |||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of period | 225,582,000 | 0 | 0 | 0 | 105,187,000 | 0 | 0 | 0 | 71,425,000 | |||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at end of period | 106,831,000 | -13,293,000 | -59,316,000 | 86,347,000 | 211,844,000 | 11,089,000 | 65,344,000 | -32,857,000 | 61,611,000 | |||||||||||||||||||||||||||||||||||
reconciliation of cash, cash equivalents and restricted cash: | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 106,515,000 | -59,318,000 | 86,346,000 | 211,526,000 | 45,086 | |||||||||||||||||||||||||||||||||||||||
restricted cash | 316,000 | 2,000 | 1,000 | 318,000 | ||||||||||||||||||||||||||||||||||||||||
total cash, cash equivalents and restricted cash | 106,831,000 | |||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of non-cash investing and financing activities: | ||||||||||||||||||||||||||||||||||||||||||||
unpaid amounts related to property and equipment | -746,000 | |||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense | 82,000 | -63,000 | 111,000 | 6,123,000 | 3,450,000 | -88,000 | 743,000 | 198,000 | -284,000 | 165,000 | 212,000 | 103,000 | ||||||||||||||||||||||||||||||||
reclassification of currency translation gain | 0 | 0 | 0 | -419,000 | ||||||||||||||||||||||||||||||||||||||||
impairment of fixed assets | 0 | 0 | 0 | 474,000 | ||||||||||||||||||||||||||||||||||||||||
loss on disposal of assets | 0 | -2 | -1 | 13 | 13 | -2 | 18 | 14 | -16 | 1 | 7 | 48 | ||||||||||||||||||||||||||||||||
acquired in-process research and development expense | 0 | 7,000 | ||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||
accrued liabilities and other current liabilities | ||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 25,000 | 25,000 | 24,000 | |||||||||||||||||||||||||||||||||||||||||
purchase of property and equipment | -151,000 | -39,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of property, plant and equipment | ||||||||||||||||||||||||||||||||||||||||||||
payments to akeso for upfront milestone payments and associated direct transaction costs | 0 | 0 | 0 | 0 | -475,015,000 | |||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock via private placements, net of offering costs | -101,000 | |||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock under at-the-market offering, net of commissions and offering costs | 72,764,000 | -4,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock for rights offering | 0 | 0 | 0 | 104,686,000 | ||||||||||||||||||||||||||||||||||||||||
transaction costs from the issuance of common stock for rights offering | ||||||||||||||||||||||||||||||||||||||||||||
re-payment of related party promissory notes | ||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rates on cash and cash equivalents | 435,000 | 588,000 | 2,620,000 | |||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of cash flow information: | ||||||||||||||||||||||||||||||||||||||||||||
cash paid for interest on related party promissory note | 82,000 | -82,000 | ||||||||||||||||||||||||||||||||||||||||||
cash paid for income taxes | 0 | 0 | 1,000 | 0 | ||||||||||||||||||||||||||||||||||||||||
leased assets obtained in exchange for operating lease liabilities | 16,241,000 | |||||||||||||||||||||||||||||||||||||||||||
unpaid amounts related to purchase of property, plant and equipment | 127,000 | 92,000 | ||||||||||||||||||||||||||||||||||||||||||
consideration for the issuance of common stock for rights offering used to satisfy a portion of a related party promissory note | 0 | 0 | 0 | 395,314,000 | ||||||||||||||||||||||||||||||||||||||||
issuance of common stock pursuant to the akeso license agreement | 0 | 0 | 0 | 45,900,000 | ||||||||||||||||||||||||||||||||||||||||
other long-term assets | ||||||||||||||||||||||||||||||||||||||||||||
proceeds received related to the exercise of warrants | 0 | 1,657,000 | 5,658,000 | 0 | ||||||||||||||||||||||||||||||||||||||||
repayment of related party promissory notes | 0 | 0 | -24,686,000 | |||||||||||||||||||||||||||||||||||||||||
proceeds received related to employee stock awards and purchase plans | 2,049,000 | 565,000 | 2,019,000 | |||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, and restricted cash | -59,316,000 | 86,347,000 | 211,844,000 | |||||||||||||||||||||||||||||||||||||||||
cash paid for interest on related party promissory notes | 0 | 0 | 1,501,000 | 2,917,000 | 3,488,000 | 1,306,000 | ||||||||||||||||||||||||||||||||||||||
offering costs included in accounts payable and accrued expenses | ||||||||||||||||||||||||||||||||||||||||||||
net income | -43,473,000 | |||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||
unrealized foreign exchange gain | 9,000 | 849,000 | 224,000 | -1,719,000 | ||||||||||||||||||||||||||||||||||||||||
upfront consideration to akeso for second amendment | ||||||||||||||||||||||||||||||||||||||||||||
increase in cash and cash equivalents | 106,657,000 | -18,324,000 | -28,853,000 | -577,638,000 | 1,192,000 | 35,777,000 | 43,083,000 | 1,700 | 9,863 | -12,153 | 4,508 | -9,864 | 34,759 | -3,234 | -9,187 | -11,955 | -6,843 | |||||||||||||||||||||||||||
gain on remeasurement of liabilities | ||||||||||||||||||||||||||||||||||||||||||||
unrealized foreign currency loss | ||||||||||||||||||||||||||||||||||||||||||||
amortization of intangible assets | 217,000 | 217,000 | 232,000 | 248,000 | 249,000 | 256,000 | 257,000 | 255,000 | 423,000 | |||||||||||||||||||||||||||||||||||
impairment of intangible assets | ||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | 0 | 3,000 | 6,000 | 350,000 | -1,412,000 | 1,227,000 | 705,000 | 455,000 | 932,000 | -1,366,000 | -590,000 | -114,000 | ||||||||||||||||||||||||||||||||
research and development tax credit receivable | -203,000 | 260,000 | -154,000 | 632,000 | -178,000 | 3,449,000 | 47,000 | 850,000 | 12,112,000 | -1,249,000 | -760,000 | -1,666,000 | 5,592,000 | -3,753,000 | -4,193,000 | -3,661,000 | -884,000 | |||||||||||||||||||||||||||
deferred revenue and other income | 276,000 | -3,422,000 | -1,474,000 | -2,658,000 | ||||||||||||||||||||||||||||||||||||||||
net receipts related to the exercise of warrants | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from related party promissory notes | 520,000,000 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
payments of related party promissory notes issuance costs | ||||||||||||||||||||||||||||||||||||||||||||
debt issuance costs in accrued expenses | 38,000 | |||||||||||||||||||||||||||||||||||||||||||
deferred transaction costs included in other non-current assets | ||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of assets | 11,000 | |||||||||||||||||||||||||||||||||||||||||||
prepaid expenses | -181,000 | 3,545,000 | -2,792,000 | 2,640,000 | 1,011,000 | -4,896,000 | 331,000 | 101,000 | 3,775,000 | -1,451,000 | 2,682,000 | 1,280,000 | -2,903,000 | 2,330,000 | 1,638,000 | -1,878,000 | ||||||||||||||||||||||||||||
other current and long-term assets | -151,000 | -275,000 | 2,531,000 | -43,000 | -2,455,000 | -1,431,000 | 508,000 | |||||||||||||||||||||||||||||||||||||
proceeds from sale of property and equipment | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock for rights offering, net of offering costs | ||||||||||||||||||||||||||||||||||||||||||||
lease assets obtained in exchange for operating lease liabilities | 0 | 0 | 4,216,000 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||
unrealized foreign exchange | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of property. plant and equipment | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
transaction costs related to the issuance of common stock for rights offering | 0 | -80,000 | -539,000 | |||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock via private placement | ||||||||||||||||||||||||||||||||||||||||||||
proceeds received related to employee stock awards | 111,000 | 485,000 | 229,000 | 0 | 651,000 | 108,000 | 0 | 187,000 | ||||||||||||||||||||||||||||||||||||
decrease in cash and cash equivalents | -32,857,000 | -9,814,000 | -1,211 | -10,633 | ||||||||||||||||||||||||||||||||||||||||
in-process research and development expense | 0 | 0 | 0 | 520,915,000 | ||||||||||||||||||||||||||||||||||||||||
other long- term liabilities | 1,763,000 | |||||||||||||||||||||||||||||||||||||||||||
transaction costs included in accrued expenses | 80,000 | 0 | 28,000 | |||||||||||||||||||||||||||||||||||||||||
amortization of operating right-of-use assets | 575,000 | 567,000 | 425,000 | 285,000 | 291,000 | 402,000 | 260,000 | 298,000 | 343,000 | 295,000 | ||||||||||||||||||||||||||||||||||
operating lease liabilities | -692,000 | -688,000 | -464,000 | -367,000 | -208,000 | -297,000 | -297,000 | -297,000 | -325,000 | -292,000 | ||||||||||||||||||||||||||||||||||
supplemental disclosure of cash flow information | ||||||||||||||||||||||||||||||||||||||||||||
cash at beginning of the period | 0 | 0 | 648,607,000 | 0 | 0 | 71,791,000 | ||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of the period | -18,324,000 | -28,853,000 | 70,969,000 | 1,192,000 | 102,194,000 | 55,296 | -11,896 | -11,396 | 36,894 | -5,813 | 21,166 | 1,316 | 38,070 | 4,917 | 12,283 | 25,050 | 33,010 | -5,367 | 14,650 | |||||||||||||||||||||||||
other adjustments | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock | ||||||||||||||||||||||||||||||||||||||||||||
transaction costs from the issuance of common stock | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of share options | 596,000 | 4 | 0 | 0 | 0 | 1 | -28 | -1 | 115 | 16 | 136 | 4 | ||||||||||||||||||||||||||||||||
effect of exchange rates on cash and restricted cash | ||||||||||||||||||||||||||||||||||||||||||||
cash at beginning of period | ||||||||||||||||||||||||||||||||||||||||||||
other current assets | 1,941,000 | -1,013,000 | -370,000 | -277,000 | -354,000 | 549,000 | 270,000 | |||||||||||||||||||||||||||||||||||||
payment of related party promissory notes issuance costs | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock for rights-offering | ||||||||||||||||||||||||||||||||||||||||||||
transaction costs related to the issuance of common stock for rights-offering | ||||||||||||||||||||||||||||||||||||||||||||
increase in cash | -20,115,000 | 5,659,000 | -8,457,000 | |||||||||||||||||||||||||||||||||||||||||
cash at end of the period | -20,115,000 | 77,450,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from related party promissory note | 25,000,000 | 55,000,000 | 55,000,000 | |||||||||||||||||||||||||||||||||||||||||
promissory note issuance costs in accrued expenses | ||||||||||||||||||||||||||||||||||||||||||||
gain on recognition of contingent consideration payable | ||||||||||||||||||||||||||||||||||||||||||||
accrued liabilities and accrued compensation | ||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rates on cash | ||||||||||||||||||||||||||||||||||||||||||||
cash at end of period | ||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of asset | ||||||||||||||||||||||||||||||||||||||||||||
deferred revenue | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock from rights offering | ||||||||||||||||||||||||||||||||||||||||||||
transaction costs on issuance of common stock from rights offering | -54,000 | |||||||||||||||||||||||||||||||||||||||||||
payments of debt issuance costs | 0 | |||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of stock options | 730,000 | 241,000 | 897,000 | |||||||||||||||||||||||||||||||||||||||||
cash flows from operating activities | ||||||||||||||||||||||||||||||||||||||||||||
deferred revenue and income | -354,000 | -1,200,000 | ||||||||||||||||||||||||||||||||||||||||||
cash flows from investing activities | ||||||||||||||||||||||||||||||||||||||||||||
purchase of intangible assets | -4 | -675 | -7 | |||||||||||||||||||||||||||||||||||||||||
cash flows from financing activities | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from issue of common stock from rights offering | ||||||||||||||||||||||||||||||||||||||||||||
repayment of related party promissory note | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of the period | 0 | 66,417,000 | 60,299 | -5,962 | -2,176 | 34,996 | -696 | 23,857 | 2,527 | 27,642 | 238 | 724 | 36,307 | -1,725 | -2,276 | 23,911 | ||||||||||||||||||||||||||||
depreciation of operating right-of-use assets | 152,000 | |||||||||||||||||||||||||||||||||||||||||||
lease liabilities | -152,000 | -118,000 | ||||||||||||||||||||||||||||||||||||||||||
loss on recognition of contingent consideration payable | -1,000 | -345 | ||||||||||||||||||||||||||||||||||||||||||
depreciation of operating lease right-of-use assets | ||||||||||||||||||||||||||||||||||||||||||||
impairment of goodwill and intangible assets | -1,109 | -138 | ||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | ||||||||||||||||||||||||||||||||||||||||||||
accounts and other receivables | ||||||||||||||||||||||||||||||||||||||||||||
contingent consideration paid | 0 | |||||||||||||||||||||||||||||||||||||||||||
other liabilities | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of the period / year | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of the period / year | ||||||||||||||||||||||||||||||||||||||||||||
other expense | ||||||||||||||||||||||||||||||||||||||||||||
deferred income | ||||||||||||||||||||||||||||||||||||||||||||
investing activities | ||||||||||||||||||||||||||||||||||||||||||||
purchase of property, plant and equipment | -31 | -2 | -34 | 170 | -59 | -109 | -362 | -28 | -16 | -27 | -10 | 25 | -53 | |||||||||||||||||||||||||||||||
financing activities | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from issue of share capital | 15,480 | -520 | 20,627 | -4,899 | 157 | -14,214 | -493 | |||||||||||||||||||||||||||||||||||||
transaction costs on share capital issued | -1,180 | 469 | 2,280 | 79 | ||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of the year | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of the year | ||||||||||||||||||||||||||||||||||||||||||||
profit before income tax | -6,711 | -8,969 | -12,721 | 26,476 | 245 | -4,277 | ||||||||||||||||||||||||||||||||||||||
cash flows from operating activities - sum | -8,969 | -12,721 | 26,476 | 245 | -9,325 | -11,463 | -4,277 | -8,812 | -9,056 | 1,484 | -8,211 | |||||||||||||||||||||||||||||||||
adjusted for: | ||||||||||||||||||||||||||||||||||||||||||||
gain on remeasurement or derecognition of financial liabilities on funding arrangements | ||||||||||||||||||||||||||||||||||||||||||||
finance income | -1 | -8 | -1 | 1,004 | -4,097 | -2 | -1 | 0 | -1 | -3 | -4 | 7 | -12 | |||||||||||||||||||||||||||||||
finance costs | 65 | 42 | 36 | 71 | 79 | -58 | 51 | 259 | 302 | |||||||||||||||||||||||||||||||||||
amortization of intangible fixed assets | 259 | 138 | 7 | |||||||||||||||||||||||||||||||||||||||||
increase in provisions | -1 | |||||||||||||||||||||||||||||||||||||||||||
share-based payment | 290 | 128 | 130 | 236 | 167 | -705 | 3,922 | 1,417 | 109 | 749 | -131 | 673 | 707 | 358 | 113 | 252 | 521 | 493 | ||||||||||||||||||||||||||
adjusted profit from operations before changes in working capital | -5,658 | -9,380 | -7,779 | 28,540 | 688 | |||||||||||||||||||||||||||||||||||||||
decrease in trade and other receivables | 476 | -746 | ||||||||||||||||||||||||||||||||||||||||||
increase in deferred revenue | 1,315 | 4,403 | ||||||||||||||||||||||||||||||||||||||||||
increase in trade and other payables | 1,967 | 4,151 | 893 | 224 | ||||||||||||||||||||||||||||||||||||||||
cash used by operations | -558 | -9,680 | -10,270 | -7,187 | -9,338 | 843 | -6,357 | |||||||||||||||||||||||||||||||||||||
taxation received | 900 | -650 | -397 | 6,381 | -61 | 3,612 | -103 | -665 | -318 | -763 | -26 | |||||||||||||||||||||||||||||||||
research and development expenditure credit received | ||||||||||||||||||||||||||||||||||||||||||||
net cash used by operating activities | -558 | -9,680 | -10,289 | |||||||||||||||||||||||||||||||||||||||||
interest received | 1 | 1 | 1 | -1 | 3 | 0 | 1 | -5 | 8 | 1 | 8 | 1 | 2 | 1 | 0 | 1 | 3 | 4 | -7 | 12 | ||||||||||||||||||||||||
net cash used by investing activities | ||||||||||||||||||||||||||||||||||||||||||||
repayment of lease liabilities | -60 | |||||||||||||||||||||||||||||||||||||||||||
repayment of lease interest | ||||||||||||||||||||||||||||||||||||||||||||
net cash generated from financing activities | 15,235 | -491 | 18,677 | 16 | 19,583 | -4,563 | 18,423 | 28 | 17 | -74 | 341 | -11 | 157 | -12,053 | -419 | |||||||||||||||||||||||||||||
loss before income tax | -9,325 | -7,716 | -2,012 | -5,827 | -8,812 | -9,056 | 1,484 | -8,211 | ||||||||||||||||||||||||||||||||||||
foreign exchange loss | -628 | 805 | -157 | 700 | 612 | 66 | -154 | -1 | ||||||||||||||||||||||||||||||||||||
adjusted loss from operations before changes in working capital | -8,643 | -9,195 | -6,376 | -870 | -4,935 | -8,413 | -8,478 | -7,653 | ||||||||||||||||||||||||||||||||||||
increase in prepayments and other receivables | -1,972 | -624 | ||||||||||||||||||||||||||||||||||||||||||
cash from operations | ||||||||||||||||||||||||||||||||||||||||||||
net cash (used in) / generated from financing activities | ||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rates in cash and cash equivalents | 3,584 | -1,178 | 1,428 | 198 | 346 | 565 | 171 | -693 | -624 | -761 | -24 | 143 | -74 | |||||||||||||||||||||||||||||||
acquisition of subsidiaries net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||
gain on re-measurement of financial liabilities on funding arrangements | ||||||||||||||||||||||||||||||||||||||||||||
foreign exchange gain | -165 | |||||||||||||||||||||||||||||||||||||||||||
research and development expenditure credit | -89 | 1 | 0 | 0 | -4 | -4 | -7 | |||||||||||||||||||||||||||||||||||||
decrease in deferred revenue | -1,616 | -3,216 | -2,325 | -2,236 | ||||||||||||||||||||||||||||||||||||||||
decrease in trade and other payables | -1,034 | -114 | ||||||||||||||||||||||||||||||||||||||||||
rdec credit received | ||||||||||||||||||||||||||||||||||||||||||||
amortisation of intangible fixed assets | 236 | 270 | 250 | 286 | 3 | 2 | 3 | 3 | 4 | 3 | -1 | 3 | ||||||||||||||||||||||||||||||||
decrease in prepayments and other receivables | -1,691 | 5,272 | -5,291 | -3,239 | -218 | 506 | -1,187 | 1,072 | ||||||||||||||||||||||||||||||||||||
net cash generated from operating activities | 1,817 | -13,857 | ||||||||||||||||||||||||||||||||||||||||||
cash (used by) / generated from operations | ||||||||||||||||||||||||||||||||||||||||||||
net cash (used by) / generated from operating activities | ||||||||||||||||||||||||||||||||||||||||||||
cash received from funding arrangements accounted for as financial liabilities | -5 | |||||||||||||||||||||||||||||||||||||||||||
gain on re-measurement or derecognition of financial liabilities on funding arrangements | ||||||||||||||||||||||||||||||||||||||||||||
movement in provisions | 10 | -4 | 10 | |||||||||||||||||||||||||||||||||||||||||
cash (used in) / generated from operations | ||||||||||||||||||||||||||||||||||||||||||||
taxation paid | -19 | |||||||||||||||||||||||||||||||||||||||||||
net cash (used in) / generated from operating activities | ||||||||||||||||||||||||||||||||||||||||||||
finance cost | 84 | 290 | 72 | |||||||||||||||||||||||||||||||||||||||||
impairment | 15 | |||||||||||||||||||||||||||||||||||||||||||
increase in trade and other receivables | -159 | |||||||||||||||||||||||||||||||||||||||||||
increase in trade and other creditors | 529 | |||||||||||||||||||||||||||||||||||||||||||
other operating income on derecognition of financial liabilities on funding arrangements | ||||||||||||||||||||||||||||||||||||||||||||
other operating income on derecognition of financial liabilities on fundingarrangements | ||||||||||||||||||||||||||||||||||||||||||||
increase in provisions for other liabilities and charges | -1 | |||||||||||||||||||||||||||||||||||||||||||
cash generated from operations | -13,754 | |||||||||||||||||||||||||||||||||||||||||||
exercise of share options | 490 | 324 | -119 | -5 | ||||||||||||||||||||||||||||||||||||||||
increase in deferred income | -8,861 | |||||||||||||||||||||||||||||||||||||||||||
cash generated from / (used by) operations | -9,090 | |||||||||||||||||||||||||||||||||||||||||||
net cash generated from / (used by) operating activities | -9,755 | |||||||||||||||||||||||||||||||||||||||||||
cash paid in respect of financial liabilites from funding arrangements | ||||||||||||||||||||||||||||||||||||||||||||
net cash (used)/generated by investing activities | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of year | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of year | ||||||||||||||||||||||||||||||||||||||||||||
profit on disposal of property, plant and equipment | ||||||||||||||||||||||||||||||||||||||||||||
adjusted loss from operations before changes in working capital and provisions | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from disposal of property, plant and equipment | ||||||||||||||||||||||||||||||||||||||||||||
net cash (used) / generated by investing activities | ||||||||||||||||||||||||||||||||||||||||||||
share-based payment expense | 550 | |||||||||||||||||||||||||||||||||||||||||||
net cash (used in) / generated by investing activities | -41 | |||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of period | -213 | |||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of period | -7,056 | |||||||||||||||||||||||||||||||||||||||||||
assets | ||||||||||||||||||||||||||||||||||||||||||||
non-current assets | ||||||||||||||||||||||||||||||||||||||||||||
goodwill | 1,018 | |||||||||||||||||||||||||||||||||||||||||||
intangible assets | 5,334 | |||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment | 97 | |||||||||||||||||||||||||||||||||||||||||||
current assets | ||||||||||||||||||||||||||||||||||||||||||||
trade and other receivables | 2,940 | |||||||||||||||||||||||||||||||||||||||||||
current tax | 2,692 | |||||||||||||||||||||||||||||||||||||||||||
total assets | 57,167 | |||||||||||||||||||||||||||||||||||||||||||
liabilities | ||||||||||||||||||||||||||||||||||||||||||||
non-current liabilities | ||||||||||||||||||||||||||||||||||||||||||||
deferred tax | -1,018 | |||||||||||||||||||||||||||||||||||||||||||
current liabilities | ||||||||||||||||||||||||||||||||||||||||||||
trade and other payables | -4,151 | |||||||||||||||||||||||||||||||||||||||||||
provisions for other liabilities and charges | -78 | |||||||||||||||||||||||||||||||||||||||||||
total liabilities | -5,247 | |||||||||||||||||||||||||||||||||||||||||||
net assets | 51,920 | |||||||||||||||||||||||||||||||||||||||||||
equity | ||||||||||||||||||||||||||||||||||||||||||||
share capital | 933 | |||||||||||||||||||||||||||||||||||||||||||
share premium account | 70,394 | |||||||||||||||||||||||||||||||||||||||||||
share-based payment reserve | 4,342 | |||||||||||||||||||||||||||||||||||||||||||
merger reserve | -2,978 | |||||||||||||||||||||||||||||||||||||||||||
special reserve | 30,645 | |||||||||||||||||||||||||||||||||||||||||||
currency translation reserve | 118 | |||||||||||||||||||||||||||||||||||||||||||
accumulated losses reserve | -51,534 | |||||||||||||||||||||||||||||||||||||||||||
total equity attributable to the equity shareholders of the parent | 51,920 | |||||||||||||||||||||||||||||||||||||||||||
net cash generated by / (used in) investing activities | ||||||||||||||||||||||||||||||||||||||||||||
(profit) / loss on disposal of property, plant and equipment | ||||||||||||||||||||||||||||||||||||||||||||
impairment charge |